SEDECAL SA recalled its Mobile X-ray system on June 10, 2025, due to cleaning safety concerns. The device is not water-resistant and improper cleaning may lead to serious consequences. Healthcare providers and patients must stop using the device immediately and follow recall instructions.
Sedecal sent an email to its consignees to remind the users that the equipment is not water-resistant and must be cleaned strictly according to the instructions in the manual, clearly outlining the possible consequences of improper cleaning.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact SEDECAL SA or your healthcare provider for instructions. Notification method: E-Mail
The affected product is the SEDECAL RF.004 Mobile X-ray system. It is distributed in California, Illinois, and New Jersey. Specific serial numbers include 75723.
The Mobile X-ray system is not water-resistant. Improper cleaning can result in malfunction or safety risks.
There are no specific reported injuries or incidents linked to this recall. However, the potential for significant harm exists if the device is not properly maintained.
Stop using the Mobile X-ray system immediately. Contact SEDECAL SA or your healthcare provider for further instructions.
For more information, visit the FDA recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-0283-2026 or call SEDECAL SA.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.